Synthesis, biological activity and conformational analysis of cyclic GRF analogs.

A novel cyclic GRF analog, cyclo(Asp8-Lys12)-[Asp8,Ala15]-GRF(1-29)-NH2, i.e. cyclo8,12[Asp8,Ala15]-GRF(1-29)-NH2, was synthesized by the solid phase procedure and found to retain significant biological activity. Solid phase cyclization of Asp8 to Lys12 proceeded rapidly (approximately 2 h) using the BOP reagent. Substitution of Ala2 with D-Ala2 and/or NH2-terminal replacement (desNH2-Tyr1 or N-MeTyr1) in the cyclo8,12[Asp8,Ala15]-GRF(1-29)-NH2 system resulted in highly potent analogs that were also active in vivo. Conformational analysis (circular dichroism and molecular dynamics calculations based on NOE-derived distance constraints) demonstrated that cyclo8,12[Asp8,Ala15]-GRF(1-29)-NH2 contains a long alpha-helical segment even in aqueous solution. A series of cyclo8,12 stereoisomers containing D-Asp8 and/or D-Lys12 were prepared and also found to be highly potent and to retain significant alpha-helical conformation. The high biological activity of cyclo8,12[N-MeTyr1,D-Ala2,Asp8,Ala15]-GRF(1-29)- NH2 may be explained on the basis of retention of a preferred bioactive conformation.

[1]  C. Selve,et al.  Reactifs de couplage peptidique I (1) - l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.) , 1975 .

[2]  K Wüthrich,et al.  A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. , 1980, Biochemical and biophysical research communications.

[3]  L. Frohman,et al.  Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. , 1986, The Journal of clinical investigation.

[4]  A. Fournier,et al.  Synthesis and biological activity of novel linear and cyclic GRF analogs , 1988 .

[5]  Ad Bax,et al.  MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy , 1985 .

[6]  P. Wright,et al.  Analysis of 1H NMR spectra of proteins using multiple-quantum coherence , 1986 .

[7]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[8]  M. Preece,et al.  RESPONSES TO ANALOGUES OF GROWTH HORMONE‐RELEASING HORMONE IN NORMAL SUBJECTS, AND IN GROWTH‐HORMONE DEFICIENT CHILDREN AND YOUNG ADULTS , 1984, Clinical endocrinology.

[9]  P. Y. Chou,et al.  Empirical predictions of protein conformation. , 1978, Annual review of biochemistry.

[10]  G. Bodenhausen,et al.  Exploring nuclear spin systems by relayed magnetization transfer , 1982 .

[11]  Y H Chen,et al.  Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. , 1972, Biochemistry.

[12]  W. Vale,et al.  Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour , 1982, Nature.

[13]  N. Ling,et al.  Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. , 1982, Science.

[14]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[15]  D. Coy,et al.  Super-active analogs of growth hormone-releasing factor (1-29)-amide. , 1984, Biochemical and biophysical research communications.

[16]  N. Ling,et al.  Invivo biological potency of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor , 1983 .

[17]  M Karplus,et al.  Solution conformations of human growth hormone releasing factor: comparison of the restrained molecular dynamics and distance geometry methods for a system without long-range distance data. , 1987, Protein engineering.

[18]  A. Gronenborn,et al.  Solution structure of human growth hormone releasing factor. Combined use of circular dichroism and nuclear magnetic resonance spectroscopy. , 1986, Journal of molecular biology.

[19]  D. States,et al.  A two-dimensional nuclear overhauser experiment with pure absorption phase in four quadrants☆ , 1982 .

[20]  M. Vance,et al.  HUMAN PANCREATIC GROWTH-HORMONE-RELEASING FACTOR SELECTIVELY STIMULATES GROWTH-HORMONE SECRETION IN MAN , 1983, The Lancet.

[21]  N. Ling,et al.  Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Edwards.  Cardio-oesophageal obstruction. , 1950, Lancet.

[23]  W. König,et al.  Eine neue Methode zur Synthese von Peptiden: Aktivierung der Carboxylgruppe mit Dicyclohexylcarbodiimid unter Zusatz von 1‐Hydroxy‐benzotriazolen , 1970 .

[24]  E. Kaiser,et al.  Amphiphilic secondary structure: design of peptide hormones. , 1984, Science.

[25]  N. Ling,et al.  Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted at position-1. , 1984, Biochemical and biophysical research communications.

[26]  K. Wüthrich.  NMR of proteins and nucleic acids , 1988 .

[27]  R. R. Ernst,et al.  Two‐dimensional spectroscopy. Application to nuclear magnetic resonance , 1976 .

[28]  N. Ueno,et al.  Synthesis and invitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor , 1984 .